NZ333095A - Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids - Google Patents

Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids

Info

Publication number
NZ333095A
NZ333095A NZ333095A NZ33309597A NZ333095A NZ 333095 A NZ333095 A NZ 333095A NZ 333095 A NZ333095 A NZ 333095A NZ 33309597 A NZ33309597 A NZ 33309597A NZ 333095 A NZ333095 A NZ 333095A
Authority
NZ
New Zealand
Prior art keywords
alkyl
methyl
inhibitors
nhe
medicament
Prior art date
Application number
NZ333095A
Inventor
Hans Jochen Lang
Hans-Willi Jansen
Jan-Robert Schwark
Heinz-Werner Kleemann
Oliver Jung
Hans-Ludwig Schaefer
Wolfgang Linz
Werner Kramer
Bernward Schoelkens
Eugen Falk
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19712636A external-priority patent/DE19712636A1/en
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NZ333095A publication Critical patent/NZ333095A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Use of Na+/H+ exchange inhibitors benzoylguanidines of the formula 1 where: R(1) or R(2) is R(6)-S(O)n- or R(7)R(8)N-02S-; and the other substituent R(1) or R(2) in each case are H, F, Cl, Br, (C1-C4)-alkyl, (C1-C4)-alkoxy or phenoxy, is unsubstituted or substituted by 1 - 3 substituents selected from F, Cl, methyl and methoxy; or the other substituent R(1) or R(2) is: R(6)-S(O)n or R(7)R(8)N-; n is 0, 1 or 2; R(6) is (C1-C6)-alkyl, (C5-C7)-cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from F, Cl, methyl and methoxy R(7) and R(8) are H or (C1-C6)-alkyl; or R(7) is phenyl-(CH2)m; m is 1-4; or R(7) is phenyl, which is unsubstituted or substituted by 1 - 2 substituents selected from F, Cl, methyl and methoxy or R(7) and R(8) together are straight chain or branched (C4-C7) chain, where the chain can additionally be interrupted by O, S or NR9; R(9) is H, Methyl; or R(7) and R(8) together with the nitrogen atom to which they are bonded are a dihydroindole tetrahydroquinoline or tetrahydroisoquinoline system; R(3), R(4} and R(5) independently are H or C1-2 alkyl or R4 and R5 are C4-7 alkylene chain
NZ333095A 1996-06-03 1997-05-20 Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids NZ333095A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19622222A DE19622222A1 (en) 1996-06-03 1996-06-03 Use of sodium=proton exchange inhibitor
DE19712636A DE19712636A1 (en) 1997-03-26 1997-03-26 Use of inhibitor of sodium/proton exchange to treat hyperlipidaemia
PCT/EP1997/002548 WO1997046226A2 (en) 1996-06-03 1997-05-20 USE OF INHIBITORS OF THE CELLULAR Na+/H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS

Publications (1)

Publication Number Publication Date
NZ333095A true NZ333095A (en) 2000-08-25

Family

ID=26026256

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333095A NZ333095A (en) 1996-06-03 1997-05-20 Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids

Country Status (23)

Country Link
EP (1) EP0918515B1 (en)
JP (1) JP4527811B2 (en)
KR (1) KR100511711B1 (en)
CN (1) CN1221339A (en)
AR (1) AR007353A1 (en)
AT (1) ATE293965T1 (en)
AU (1) AU722166B2 (en)
BR (1) BR9709516A (en)
CA (1) CA2257299A1 (en)
DE (2) DE19622222A1 (en)
DK (1) DK0918515T3 (en)
ES (1) ES2241049T3 (en)
IL (1) IL126935A0 (en)
NO (1) NO985480L (en)
NZ (1) NZ333095A (en)
PL (1) PL189950B1 (en)
PT (1) PT918515E (en)
RU (1) RU2211032C2 (en)
SI (1) SI0918515T1 (en)
SK (1) SK165898A3 (en)
TR (1) TR199802505T2 (en)
WO (1) WO1997046226A2 (en)
ZA (1) ZA974828B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
DE19859727A1 (en) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh The use of inhibitors of the sodium-hydrogen exchanger for the manufacture of a medicament for the prevention of age-related organ dysfunctions, age-related illnesses for the prolongation of life
EP1180029A4 (en) 1999-04-23 2002-10-02 Bristol Myers Squibb Co Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
DE19945302A1 (en) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenyl derivatives as NHE-3 inhibitors
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
FR2856062B1 (en) * 2003-06-12 2005-11-11 Aventis Pharma Sa 3-GUANIDINOCARBONYL-HETEROCYCLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
US7230007B2 (en) 2003-06-12 2007-06-12 Sanofi-Aventis Deutschland Gmbh Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
CA2529949C (en) * 2003-06-26 2013-08-06 Biotron Limited Antiviral compounds and methods
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
DE602006004964D1 (en) 2005-02-10 2009-03-12 Bristol Myers Squibb Co DIHYDROCHINAZOLINONE AS 5HT MODULATORS
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (en) 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
KR20110135411A (en) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
JP2013518129A (en) 2010-01-28 2013-05-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ Compositions and methods for improving proteasome activity
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
BR112021000139A2 (en) 2018-07-19 2021-04-06 Astrazeneca Ab METHODS OF TREATMENT OF HFPEF USING DAPAGLIFLOZINE AND COMPOSITIONS UNDERSTANDING THE SAME

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110817A (en) * 1988-10-21 1992-05-05 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920123A (en) * 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
AU7316591A (en) * 1990-02-28 1991-09-18 Upjohn Company, The Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
DE59403818D1 (en) * 1993-02-20 1997-10-02 Hoechst Ag Substituted benzoylguanidines, processes for their preparation, their use as medicaments, as inhibitors of cellular Na + / H + exchange or as diagnostic agents and medicaments containing them
DE4318658A1 (en) * 1993-06-04 1994-12-08 Hoechst Ag Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
DE4325822A1 (en) * 1993-07-31 1995-02-02 Hoechst Ag Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
IL114670A0 (en) * 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof

Also Published As

Publication number Publication date
SK165898A3 (en) 1999-05-07
PT918515E (en) 2005-06-30
WO1997046226A2 (en) 1997-12-11
BR9709516A (en) 1999-08-10
IL126935A0 (en) 1999-09-22
NO985480D0 (en) 1998-11-24
AU722166B2 (en) 2000-07-20
ATE293965T1 (en) 2005-05-15
AU2957697A (en) 1998-01-05
PL189950B1 (en) 2005-10-31
NO985480L (en) 1999-01-28
CN1221339A (en) 1999-06-30
JP2000506906A (en) 2000-06-06
JP4527811B2 (en) 2010-08-18
RU2211032C2 (en) 2003-08-27
KR20000016240A (en) 2000-03-25
ZA974828B (en) 1997-12-03
EP0918515B1 (en) 2005-04-27
DK0918515T3 (en) 2005-08-15
SI0918515T1 (en) 2005-12-31
DE19622222A1 (en) 1997-12-04
WO1997046226A3 (en) 1998-03-05
AR007353A1 (en) 1999-10-27
ES2241049T3 (en) 2005-10-16
TR199802505T2 (en) 1999-04-21
EP0918515A2 (en) 1999-06-02
PL330412A1 (en) 1999-05-10
CA2257299A1 (en) 1997-12-11
KR100511711B1 (en) 2005-12-26
DE59712287D1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
NZ333095A (en) Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
AU631007B2 (en) Benzoylguanidines, process for their preparation, their use as drugs and drugs in which they are present
CA2106613A1 (en) Benzoylguanidines, process for their preparation, their use as a medicament and medicament containing them
ES8702400A1 (en) 7-Amino-1-cyclopropyl-6,8-dihalo-1,4-dihydro-4-oxo-3-quinoline-carboxylic acids, process for their preparation and bactericidal agents containing them.
ES2006142A6 (en) Quinolinecarboxylic acid derivatives.
ES8802148A1 (en) Quinolonecarboxylic acid derivatives.
CA2045857A1 (en) Diaminotrifluoromethylpyridine Derivatives, Process for Their Production and Phospholipase A2 Inhibitor Containing Them
ES8602773A1 (en) 1,2,4-Triazol-1-yl-derivatives.
ES8801205A1 (en) Isatin derivatives, compositions containing the same, and the use thereof for ulcer diseases.
MY104048A (en) New allylaminoethylazoles.
DE3482109D1 (en) DERIVATIVES OF PHENYL ACETANILIDE.
ES8800147A1 (en) New 3-substd. carbamoyl-pyrroline and pyrrolidine derivs.
KR830003479A (en) Method for preparing 2-alkoxyphenyl-imidazo [4,5-b] pyridine

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)